Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19.
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
14
11
2021
revised:
29
03
2022
accepted:
30
03
2022
pubmed:
14
5
2022
medline:
7
7
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
WHO has established a Global Clinical Platform for the clinical characterisation of COVID-19 among hospitalised individuals. We assessed whether people living with HIV hospitalised with COVID-19 had increased odds of severe presentation and of in-hospital mortality compared with individuals who were HIV-negative and associated risk factors. Between Jan 1, 2020, and July 1, 2021, anonymised individual-level data from 338 566 patients in 38 countries were reported to WHO. Using the Platform pooled dataset, we performed descriptive statistics and regression analyses to compare outcomes in the two populations and identify risk factors. Of 197 479 patients reporting HIV status, 16 955 (8·6%) were people living with HIV. 16 283 (96.0%) of the 16 955 people living with HIV were from Africa; 10 603 (62·9%) were female and 6271 (37·1%) were male; the mean age was 45·5 years (SD 13·7); 6339 (38·3%) were admitted to hospital with severe illness; and 3913 (24·3%) died in hospital. Of the 10 166 people living with HIV with known antiretroviral therapy (ART) status, 9302 (91·5%) were on ART. Compared with individuals without HIV, people living with HIV had 15% increased odds of severe presentation with COVID-19 (aOR 1·15, 95% CI 1·10-1·20) and were 38% more likely to die in hospital (aHR 1·38, 1·34-1·41). Among people living with HIV, male sex, age 45-75 years, and having chronic cardiac disease or hypertension increased the odds of severe COVID-19; male sex, age older than 18 years, having diabetes, hypertension, malignancy, tuberculosis, or chronic kidney disease increased the risk of in-hospital mortality. The use of ART or viral load suppression were associated with a reduced risk of poor outcomes; however, HIV infection remained a risk factor for severity and mortality regardless of ART and viral load suppression status. In this sample of hospitalised people contributing data to the WHO Global Clinical Platform for COVID-19, HIV was an independent risk factor for both severe COVID-19 at admission and in-hospital mortality. These findings have informed WHO immunisation policy that prioritises vaccination for people living with HIV. As the results mostly reflect the data contribution from Africa, this analysis will be updated as more data from other regions become available. None. For the French translation of the abstract see Supplementary Materials section.
Sections du résumé
BACKGROUND
WHO has established a Global Clinical Platform for the clinical characterisation of COVID-19 among hospitalised individuals. We assessed whether people living with HIV hospitalised with COVID-19 had increased odds of severe presentation and of in-hospital mortality compared with individuals who were HIV-negative and associated risk factors.
METHODS
Between Jan 1, 2020, and July 1, 2021, anonymised individual-level data from 338 566 patients in 38 countries were reported to WHO. Using the Platform pooled dataset, we performed descriptive statistics and regression analyses to compare outcomes in the two populations and identify risk factors.
FINDINGS
Of 197 479 patients reporting HIV status, 16 955 (8·6%) were people living with HIV. 16 283 (96.0%) of the 16 955 people living with HIV were from Africa; 10 603 (62·9%) were female and 6271 (37·1%) were male; the mean age was 45·5 years (SD 13·7); 6339 (38·3%) were admitted to hospital with severe illness; and 3913 (24·3%) died in hospital. Of the 10 166 people living with HIV with known antiretroviral therapy (ART) status, 9302 (91·5%) were on ART. Compared with individuals without HIV, people living with HIV had 15% increased odds of severe presentation with COVID-19 (aOR 1·15, 95% CI 1·10-1·20) and were 38% more likely to die in hospital (aHR 1·38, 1·34-1·41). Among people living with HIV, male sex, age 45-75 years, and having chronic cardiac disease or hypertension increased the odds of severe COVID-19; male sex, age older than 18 years, having diabetes, hypertension, malignancy, tuberculosis, or chronic kidney disease increased the risk of in-hospital mortality. The use of ART or viral load suppression were associated with a reduced risk of poor outcomes; however, HIV infection remained a risk factor for severity and mortality regardless of ART and viral load suppression status.
INTERPRETATION
In this sample of hospitalised people contributing data to the WHO Global Clinical Platform for COVID-19, HIV was an independent risk factor for both severe COVID-19 at admission and in-hospital mortality. These findings have informed WHO immunisation policy that prioritises vaccination for people living with HIV. As the results mostly reflect the data contribution from Africa, this analysis will be updated as more data from other regions become available.
FUNDING
None.
TRANSLATION
For the French translation of the abstract see Supplementary Materials section.
Identifiants
pubmed: 35561704
pii: S2352-3018(22)00097-2
doi: 10.1016/S2352-3018(22)00097-2
pmc: PMC9090268
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e486-e495Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.
Déclaration de conflit d'intérêts
Declaration of interests RH received funding from the Wellcome Trust, Canadian Institute of Health Research, UK Research and Innovation/Medical Research Council, and International COVID-19 Data Alliance–Health Data Research UK. All other authors declare no competing interests.
Références
Lancet HIV. 2020 Apr;7(4):e279-e293
pubmed: 32243826
Sci Rep. 2021 Mar 18;11(1):6283
pubmed: 33737527
AIDS. 2020 Nov 1;34(13):F3-F8
pubmed: 32796217
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
JAMA Netw Open. 2021 Feb 1;4(2):e2037069
pubmed: 33533933
Mycopathologia. 2020 Aug;185(4):599-606
pubmed: 32737747
Medicine (Baltimore). 2017 Jan;96(4):e5769
pubmed: 28121924
Clin Infect Dis. 2021 Jan 27;72(2):340-350
pubmed: 33501974
HIV Med. 2021 Jan;22(1):e1-e2
pubmed: 32829525
J Med Virol. 2021 May;93(5):2971-2978
pubmed: 33506953
Lancet HIV. 2021 May;8(5):e294-e305
pubmed: 33915101
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
Rev Med Virol. 2021 Jan;31(1):1-12
pubmed: 32875716
HIV Med. 2020 Oct;21(9):567-577
pubmed: 32671970
Top Antivir Med. 2021 Apr-May;29(2):344-351
pubmed: 34107204
AIDS. 2021 Mar 15;35(4):F1-F10
pubmed: 33587448
J Infect. 2021 Aug;83(2):217-227
pubmed: 34051225
Lancet HIV. 2021 Nov;8(11):e701-e710
pubmed: 34655549
Lancet HIV. 2020 Aug;7(8):e554-e564
pubmed: 32473657
Lancet HIV. 2021 Nov;8(11):e690-e700
pubmed: 34655550
AIDS. 2020 Oct 1;34(12):1775-1780
pubmed: 32773471
Lancet HIV. 2021 Sep;8(9):e554-e567
pubmed: 34363789
AIDS Behav. 2021 Jan;25(1):85-92
pubmed: 32734438
South Afr J HIV Med. 2021 Apr 15;22(1):1220
pubmed: 33936793
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Cytokine Growth Factor Rev. 2020 Aug;54:62-75
pubmed: 32513566